Journal article
Intranasal Delivery of Mesenchymal Stromal Cells Protects against Neonatal Hypoxic-Ischemic Brain Injury
Courtney A McDonald, Zlatikha Djuliannisaa, Maria Petraki, Madison CB Paton, Tayla R Penny, Amy E Sutherland, Margie Castillo-Melendez, Iona Novak, Graham Jenkin, Michael C Fahey, Suzanne L Miller
International Journal of Molecular Sciences | MDPI | Published : 2019
DOI: 10.3390/ijms20102449
Abstract
Cerebral palsy (CP) is a permanent motor disorder that results from brain injury and neuroinflammation during the perinatal period. Mesenchymal stromal cells (MSCs) have been explored as a therapy in multiple adult neuroinflammatory conditions. Our study examined the therapeutic benefits of intranasal delivery of human umbilical cord tissue (UC) derived-MSCs in a rat model of neonatal hypoxic-ischemic (HI) brain injury. To do this, HI was performed on postnatal day 10 Sprague-Dawley rat pups via permanent ligation of the left carotid artery, followed by a hypoxic challenge of 8% oxygen for 90 min. A total of 200,000 UC-MSCs (10 million/kg) were administered intranasally 24 h post-HI. Motor c..
View full abstractGrants
Awarded by Cerebral Palsy Alliance Australia Early Career Fellowship
Awarded by Cerebral Palsy Alliance Project Grant
Funding Acknowledgements
C.A.M. is supported by a National Health and Medical Research Council and Cerebral Palsy Alliance Australia Early Career Fellowship (APP1110195). S.L.M. is supported by a National Health and Medical Research Council Senior Research Fellowship. This work is supported by Cerebral Palsy Alliance Project Grant (PG07917) and the Victorian Government's Operational Infrastructure Support Program.